Lab Clinico Central De La Montana

Summary Statement of Deficiencies D0000 An offsite Proficiency Test (PT) Desk Review was performed on February 3, 2026 to Laboratorio Clinico Central de la Montaa, the laboratory was found out of compliance with the following conditions: 42 CFR 493.803 Proficiency Testing, Successful Participation 42 CFR 493.1403 Laboratory Director, Moderate complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- two (2) out of two (2) consecutive testing events for the subspecialty of endocrinology in the analyte for T Uptake tests. Refer to D2107. D2107 ENDOCRINOLOGY CFR(s): 493.843(f) (f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events for the subspecialty of endocrinology in the analyte for T Uptake tests. The findings include: 1. Review of the Casper Report 0155D and PRPTSP scores on January 26, 2026, confirmed that the laboratory had a PT (Proficiency Test) failure for the analyte T Uptake tests in the subspecialty of endocrinology. The laboratory obtained the following testing scores: Analyte: T Uptake a. Second testing event year 2025 - 0% b. Third testing event year 2025 - 0% 2. A review of the PRPTSP records confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory director failed to provide overall management and direction samples were tested as required. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) (year 2025), the laboratory director failed to ensure successful participation in an HHS-approved proficiency testing program. Refer to D2107. -- 2 of 2 --

Summary Statement of Deficiencies D5014 GENERAL IMMUNOLOGY CFR(s): 493.1208 If the laboratory provides services in the subspecialty of General immunology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, and 493.1281 through 493.1299. This CONDITION is not met as evidenced by: Based on Mycoplasma pneumoniae quality control records patient records review from January 1, 2021 to September 9, 2021 and interview with the laboratory director and general supervisor on September 10, 2021 at 10:35 AM, it was determined that the laboratory failed to meet the requirements in the subspecialty of General Immunology. The finding includes: 1. The laboratory did not include an external positive and a negative control material each day of patient testing. Refer to : 5449- The laboratory did not include positive and negative control material. D5449 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(ii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each qualitative procedure, include a negative and positive control material; (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on General Immunology (Mycoplasma Pneumoniae test) quality control records review from January 1, 2021 to September 9, 2021, interview with the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- laboratory director and general supervisor on September 10, 2021 at 10:35 AM , it was determined that the laboratory failed to include a negative and positive control material when performed Mycoplasma pneumoniae test by Immuno Card method. The findings include : 1. The laboratory performed Mycoplasma pneumoniae test by Immuno Card method. 2. Review of the Mycoplasma pneumoniae quality control logs, showed that the laboratory did not include a negative and positive control material each day of testing from January 1, 2021 to September 9, 2021. 3. The laboratory performed and reported 1,660 patient samples from January 1, 2021 to September 9, 2021. 4. The laboratory director and general supervisor confirmed on September 10, 2021 at 10:35 AM, that the laboratory failed to include a negative and positive control material each day of testing when performed Mycoplasma pneumoniae test by Immuno Card method. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on general immunology (Mycoplasma pneumoniae) quality control records review from January 1, 2021 to September 9, 2021, laboratory director and general supervisor interview on September 10, 2021 at 10:35 AM, it was determined that the laboratory director failed to ensure compliance with the requirement for analytic systems. Refer to D 5449. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on general immunology (Mycoplasma pneumonia IgM) quality control records and interview with the laboratory director and general supervisor on September 10, 2021 at 10:35 AM, it was determined that the laboratory director did not make sure to include a positive and a negative control material each day of patient testing for Mycoplasma pneumonia tests. The finding includes: 1. The laboratory did not include a positive and a negative control material when performed Mycoplasma pneumoniae IgM each day of patient testing. Refer to D5449. D6144 GENERAL SUPERVISOR RESPONSIBILITIES CFR(s): 493.1463 The general supervisor is responsible for day-to-day supervision or oversight of the laboratory operation and personnel performing testing and reporting test results. This STANDARD is not met as evidenced by: -- 2 of 3 -- Based on general immunology (Mycoplasma pneumoniae) quality control records review from January 1, 2021 to September 9, 2021 and laboratory general supervisor interview on September 10, 2021 at 10:35 AM, it was determined that the general supervisor failed to ensure compliance with the requirement for analytic systems. The finding includes: 1. The laboratory did not include a positive and a negative control material when performed Mycoplasma IgM each day of patient testing. Refer to D5449. -- 3 of 3 --

Summary Statement of Deficiencies D5024 HEMATOLOGY CFR(s): 493.1215 If the laboratory provides services in the specialty of Hematology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, 493.1269, and 493. 1281 through 493.1299. This CONDITION is not met as evidenced by: Based on hematology quality control records ( year 2018-2019), and interview with the laboratory director on July 9, 2019 at 11:00 A.M., it was determined that the laboratory failed to ensure compliance with the analytic system requirements for hematology. The finding includes: 1. The laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). Refer to D5401. D5203 SPECIMEN IDENTIFICATION AND INTEGRITY CFR(s): 493.1232 The laboratory must establish and follow written policies and procedures that ensure positive identification and optimum integrity of a patient's specimen from the time of collection or receipt of the specimen through completion of testing and reporting of results. This STANDARD is not met as evidenced by: Based on review of Quality Assessment records ( 2018-2019), Quality Assessment (QA) written procedures review and laboratory director interview on July 9, 2019 at 12:30 P.M., it was determined that the laboratory failed to follow the written procedures to ensure the positive identification and optimum integrity of patient Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 5 -- specimen from the time of collection or receipt through completion of testing and reporting of results. The findings include: 1. The laboratory written procedures establishes that the specimen identification and optimum integrity must be evaluated annually. 2. The laboratory director stated on July 9, 2019 at 12:30 P.M., that the laboratory did not perform an evaluation to ensure positive identification and optimum integrity of a patient's specimen that are under the laboratory control since 2017. D5291 GENERAL LABORATORY SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1239(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and, when indicated, correct problems identified in the general laboratory systems requirements specified at 493.1231 through 493.1236. This STANDARD is not met as evidenced by: Based on quality assessment procedure manual, quality assessment records review (2018-2019) and laboratory director interview on jULY 9, 2019 at 12:30 P.M., it was determined that the laboratory failed to follow the established Quality Assessment Program to monitor and evaluate the following requirements for general laboratory systems: ensure the positive identification and optimum integrity of patient specimen . The findings include: 1. The laboratory quality assessment procedure manual establishes that the specimen identification and optimum integrity must be evaluated annually. 2. The laboratory director stated on July 9, 2019 at 12:30 P.M., that the laboratory did not perform an evaluation to ensure positive identification and optimum integrity of a patient's specimen that are under the laboratory control since 2017. D5391 PREANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1249(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the preanalytic systems specified at 493.1241 through 493.1242. This STANDARD is not met as evidenced by: Based on quality assessment procedure manual, quality assessment records review (2018-2019) and laboratory director interview on July 9, 2019 at 12:15 P.M., it was determined that the laboratory failed to follow the established Quality Assessment Program to monitor and evaluate the following requirements for pre analytic laboratory systems: test request. The findings include: 1. Review of the quality assessment procedure manual showed that evaluations to test requisitions must perform annually. 2. Review of the quality assessment records showed that the laboratory did not evaluate the test requisitions since 2017. 3. The laboratory director confirmed on July 9, 2019 at 12:15 P..M. that evaluations to test requisitions were not performed since 2017. D5401 PROCEDURE MANUAL CFR(s): 493.1251(a) -- 2 of 5 -- A written procedures manual for all tests, assays, and examinations performed by the laboratory must be available to, and followed by, laboratory personnel. Textbooks may supplement but not replace the laboratory's written procedures for testing or examining specimens. This STANDARD is not met as evidenced by: Based on lack of hematology records and laboratory director interview on July 9, 2019 at 11:00 a.m. , it was determined that the laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). The findings include: 1. . The laboratory perform PT ( Prothrombin time ) and PTT ( Partial thromboplastin time) tests by ACL ELITE PRO system. 2. The laboratory had in routine use on July 9, 2019 the following recombiplastin reagent: Lot. # N587757, exp. 5/2020. 3. The record showed that the laboratory began to use this new lot on October 2018. 4. Hematology records were reviewed since January 2018. The records showed that the laboratory did not document nor establish a normal population prothrombin (PT) mean for this recombiplastin new lot number used in October 2018. 5. The laboratory processed and reported 1,034 patient's samples since October 2018 with the incorrect INR. The laboratory uses the former laboratory PT mean of 12.0 secs. 6. The laboratory director stated on July 9, 2019 at 11:00 A.M, that the laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). D5411 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(a) Test systems must be selected by the laboratory. The testing must be performed following the manufacturer's instructions and in a manner that provides test results within the laboratory's stated performance specifications for each test system as determined under 493.1253. This STANDARD is not met as evidenced by: Based on manufacturer's instructions, syphilis serology quality control records review ( year 2018-2019) and laboratory director interview at 11:20 A.M. on July 9, 2019, it was determined that the laboratory failed to perform syphilis serology test as required by manufacturer's instructions by ASI RPR method. The findings include: 1. The manufacturer's establishes that the RPR (Rapid plasma reagin) test must be performed at room temperature between 20 C to 30 C . 2. Review of syphilis serology records from January 2019 to February 2019, the records showed that the laboratory processed and reported 761 RPR (Rapid plasma reagin) patient's tests that was performed at temperatures below 20 C during 35 days. 3. Review of syphilis serology records from May 2019 to June 2019, the records showed that the laboratory processed and reported 497 RPR (Rapid plasma reagin) patient's tests that was performed at temperatures below 20 C during 25 of 39 days. 4. The laboratory director confirmed that the laboratory performed RPR (Rapid plasma reagin) tests below the range established by the manufacturer's 74 days from January 2019 to June 2019. D5777 COMPARISON OF TEST RESULTS CFR(s): 493.1281(b)(c) (b) The laboratory must have a system to identify and assess patient test results that -- 3 of 5 -- appear inconsistent with the following relevant criteria, when available: (b)(1) Patient age. (b)(2) Sex. (b)(3) Diagnosis or pertinent clinical data. (b)(4) Distribution of patient test results. (b)(5) Relationship with other test parameters. (c) The laboratory must document all test result comparison activities. This STANDARD is not met as evidenced by: Based on review of quality assessment ( QA) written procedures, quality assessment records review (2018-2019) and laboratory director interview on July 9, 2019 at 12:15 P. M., it was determined that the laboratory failed to follow the established Quality Assessment Program to monitor and evaluate patient tests results for inconsistencies with patient information. The findings include: 1. The QA written procedures stated that the laboratory monitor and evaluate patient tests results for inconsistencies with patient information. 2. The quality assessment records showed that the laboratory did not evaluate nor document any test inconsistency since 2017. 3. The laboratory director stated on July 9, 2019 at 12:15 P..M. that information regarding test inconsistencies were not documented as established in the QA procedure manual since 2017. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on hematology quality control records review ( 2018-2019) and interview with the laboratory director on July 9, 2019 at 11:30 A.M., it was determined that the laboratory director failed to fulfill his responsibilities and duties to ensure compliance with the laboratory analytical system requirements for hematology. The finding includes: 1. The laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). Refer to D6093. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on hematology and syphilis serology quality control records review from January 2018 to June 2019 and laboratory director interview at 11:30 AM on July 9, 2019, it was determined that laboratory director failed to ensure compliance with the requirements for analytic systems. The findings include: 1. The laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). Refer to D5401. 2. The laboratory failed to perform syphilis serology test as required by manufacturer's instructions by ASI RPR method. Refer to D5411. D6094 LABORATORY DIRECTOR RESPONSIBILITIES -- 4 of 5 -- CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality assessment programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on Quality Assessment (QA) records review ( 2018-2019) and laboratory director interview on July 9, 2019 at 12:30 P..M, it was determined that laboratory failed to ensure compliance with quality assessment (QA) requirements. The findings include: 1. Quality Assessment records showed that the laboratory did not evaluate the established Quality Assessment Program to monitor and evaluate the requirements for laboratory general systems, preanalytic and analytic systems. 2. The laboratory director confirmed on July 9, 2019 at 12:30 P.M., that failed to evaluate the requirements for laboratory general systems, preanalytic and analytic systems. Refer to D5291 and D5391. D6177 TESTING PERSONNEL RESPONSIBILITIES CFR(s): 493.1495(b)(3) Each individual performing high complexity testing must adhere to the laboratory's quality control policies, document all quality control activities, instrument and procedural calibrations and maintenance performed. This STANDARD is not met as evidenced by: Based on review of hematology and syphilis serology quality control records and interview with the laboratory director on July 9, 2019 at 12:00 P.M., it was determined that the testing personnel did not follow written policies for quality control procedures. The findings include: 1. The laboratory failed to follow the manufacturer's instructions for calculating INR (International Normalized Ratio). Refer to D5401. 2. The laboratory failed to perform syphilis serology test as required by manufacturer's instructions by ASI RPR method. Refer to D5411. -- 5 of 5 --